J&J medtech sales rise 2.5% as orthopedics spinoff weighs
Johnson & Johnson said medical technology sales rose 2.5% but missed estimates, while it is leaning toward spinning off its orthopedics business. The combination puts pressure on J&J to show that portfolio restructuring can offset slower growth in a major operating segment.
STOCK PHOTO · FABIO RICCOBONOThe story
Johnson & Johnson reported a 2.5% increase in medical technology sales, below estimates, and is leaning toward a spinoff of its orthopedics business, according to Bloomberg Television on Oct. 13.
The update points to two separate developments in J&J’s medtech portfolio: weaker-than-expected sales growth and a possible change in ownership for orthopedics. The timing and structure of any transaction remain open.
J&J’s full-year 2025 revenue was $94.2 billion, up 6.0% year over year, with a 28.5% net margin and diluted EPS of $11.03. Those figures cover the broader company and an earlier period, rather than the reported medtech result.
The immediate unresolved points are the size and scope of the proposed orthopedics spinoff, its timing, and whether the segment’s sales trajectory improves. Future company updates should clarify the portfolio plan and provide the next comparable medtech sales figure.
Our read · Tue, Oct 13
Johnson & Johnson’s medtech sales rose 2.5% as it leaned toward spinning off its orthopedics business.
Why. The setup is mixed: slower-than-expected medtech growth raises execution questions, while a possible orthopedics separation could sharpen J&J’s portfolio. J&J’s FY2025 revenue was $94.2 billion, up 6.0% year over year, with a 28.5% net margin, but those broader and older figures do not resolve the segment-level question.
Both cases
What could change this view: The read changes if J&J abandons the orthopedics spinoff or reports a materially different medtech sales trajectory at its next update.
Who reported it · 1
Keep reading
Latest on the Wire
Former BOJ economist sees December hike and 2% terminal rateUS job growth expected to pick up in October, with moderation in wage gainsRepublican lawmakers seek Jensen Huang briefing after China spying reportsFive9 shares drop 22% after weak fourth-quarter EPS outlookTesla and SpaceX lose $456 billion as Musk-linked selloff deepensContinue on the Wire →Latest on the Wire
Nvidia plunges 9% as AI selloff erases $2.3 trillion in valueBOE Sees Case for Another Rate Hike If Iran War Doesn't EndBarkin sees interest rate hikes ahead, but at a gradual paceUS jobless claims fall to 189,000 as payrolls test labor-market strengthContinue on the Wire →Top this week
Democrats sweep Congress, setting Trump up for legislative gridlockFutures rebound after blue sweep as dollar slides and gold tops $4,000Bitcoin plunges as AI chip selling drags Nasdaq down more than 2%Trump’s Republican Party faces a midterm verdict from US voters todayBitcoin faces renewed pressure as Binance hack intensifies market fearAbout this report
Reported by Bloomberg Television as J&J Medtech Sales Disappoint, Considers Orthopedic Spinoff
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →